My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 16

Summary and Forward Looking for RCC

In her concluding remarks, Laurence Albiges, MD, PhD, shares her final thoughts and expresses optimism for the future landscape of renal cell carcinoma treatments.

EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC
EP. 2: Extended Follow Up of KEYNOTE-B61
EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma
EP. 6: Use of Combination Regimens in Frontline RCC
EP. 7: Treatment Decision Making in first-line combinations for advanced RCC
EP. 8: AE Management for Combination Regimens in Advanced RCC
EP. 9: AE Management for Combination Regimens in Advanced RCC
EP. 10: Optimizing Treatment in Advanced RCC
EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile
EP. 12: Updates in the Treatment Approach for Non-clear cell RCC
EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC
EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)
Now Viewing
EP. 16: Summary and Forward Looking for RCC